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Morbidity from in-hospital complications is
greater than treatment failure in patients
with Staphylococcus aureus bacteraemia
Natasha E. Holmes1,2*, J. Owen Robinson3,4, Sebastiaan J. van Hal5,6, Wendy J. Munckhof7,8, Eugene Athan9,10,11,
Tony M. Korman12,13, Allen C. Cheng14,15, John D. Turnidge16,17, Paul D. R. Johnson1,11,18,
Benjamin P. Howden1,2,18,19 and VANESSA study group, on behalf of the Australasian Society for Infectious
Diseases (ASID) Clinical Research Network (CRN)
Abstract
Background: Various studies have identified numerous factors associated with poor clinical outcomes in patients
with Staphylococcus aureus bacteraemia (SAB). A new study was created to provide deeper insight into in-hospital
complications and risk factors for treatment failure.
Methods: Adult patients hospitalised with Staphylococcus aureus bacteraemia (SAB) were recruited
prospectively into a multi-centre cohort. The primary outcome was treatment failure at 30 days (composite
of all-cause mortality, persistent bacteraemia, or recurrent bacteraemia), and secondary measures included
in-hospital complications and mortality at 6- and 12-months. Data were available for 222 patients recruited
from February 2011 to December 2012.
Results: Treatment failure at 30-days was recorded in 14.4% of patients (30-day mortality 9.5%). Multivariable
analysis predictors of treatment failure included age > 70 years, Pitt bacteraemia score ≥ 2, CRP at onset of
SAB > 250 mg/L, and persistent fevers after SAB onset; serum albumin at onset of SAB, receipt of appropriate
empiric treatment, recent healthcare attendance, and performing echocardiography were protective. 6-month
and 12-month mortality were 19.1% and 24.2% respectively. 45% experienced at least one in-hospital
complication, including nephrotoxicity in 19.5%.
Conclusions: This study demonstrates significant improvements in 30-day outcomes in SAB in Australia.
However, we have identified important areas to improve outcomes from SAB, particularly reducing renal
dysfunction and in-hospital treatment-related complications.
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Background
Staphylococcus aureus bacteraemia (SAB) remains an
important and frequent cause of morbidity and mortality
in hospitalised patients in spite of antimicrobial therapy,
availability of supportive care, and improvements in
hand hygiene and infection prevention. Much re-
search has been undertaken in order to elucidate risk
factors for mortality or treatment failure in patients
with SAB, and these can be categorised broadly as
factors related to the host, the pathogen, or anti-
microbial treatment [1, 2]. Many of these studies have
been retrospective in nature. We were interested in
identifying risk factors associated with treatment fail-
ure and mortality of SAB, and describing in-hospital
complications related to treatment and hospitalisation
as well as long-term outcomes. A new prospective
multi-centre cohort of patients with SAB was created
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to provide deeper insight into host and pathogen fac-
tors associated with treatment outcome and in-
hospital complications.
Methods
Study design and population
The VANESSA (Vancomycin Efficacy in Staphylococcal
Sepsis in Australia) cohort was established as a prospect-
ive observational study of patients with SAB in Australia.
Eight urban tertiary referral hospitals recruited hospita-
lised adult patients (age ≥ 18 years) with at least one
blood culture positive for SAB, including methicillin-
susceptible S. aureus (MSSA) and methicillin-resistant S.
aureus (MRSA), from 1 February 2011 to 31 December
2012. Potential participants were screened and
approached by site investigators after SAB had been con-
firmed in the microbiology laboratory. Exclusion criteria
included: 1) polymicrobial bacteraemia (including pos-
sible contaminants such as coagulase negative staphylo-
cocci, alpha-haemolytic streptococci or coryneform
bacteria); 2) hospital admission to a non-study site or no
hospitalisation; 3) transfer from another hospital with
diagnosis of SAB but no positive blood culture at
study site; 4) failure to provide informed consent. Re-
peat blood cultures were collected every 24-48 hours
after diagnosis of SAB to document clearance of bac-
teraemia. Participants were followed for 12 months
after the onset of SAB.
Outcome measures
The 30-day composite endpoint of treatment failure
comprised all-cause mortality, persistent bacteraemia
(defined as positive blood cultures for seven or more
days), or recurrent bacteraemia (defined as new positive
blood cultures within 30 days of the index blood culture
after documented clearance for 48 hours or more). Sec-
ondary outcomes included 30-day attributable mortality
as defined by Lodise et al. (positive blood cultures for
SAB at time of death, death occurred before resolution
of symptoms and signs of SAB, death occurred within 14
days after onset of SAB without another explanation,
autopsy findings indicated SAB as cause of death, death
certificated indicated SAB as cause of death) [3], long-
term mortality at 6-months and 12-months, and treat-
ment complications (in-hospital and antibiotic-related).
Data collection
Clinical data collection was performed on standardised case
record forms and comprised demographics, risk factors for
S. aureus acquisition, comorbidities [4], disease severity
markers [5–7], clinical manifestations and laboratory pa-
rameters (refer Additional file 1). More than one clinical
manifestation or site of metastatic infection was permitted
per patient. Uncomplicated bacteraemia was defined as an
absence of a defined infection syndrome (eg. severe sepsis
including shock, endocarditis, pneumonia, osteoarticular,
skin and soft tissue, deep abscess, meningitis or central
nervous system, epidural abscess), or the presence of a re-
movable focus such as a peripheral intravenous catheter
with no other manifestations. Endocarditis was defined
according to the modified Duke criteria [8]. Pre-defined in-
hospital treatment complications were persistent renal
impairment not returning to baseline within 30 days after
onset of SAB, requirement for inpatient rehabilitation, per-
sistent fevers for 7 or more days after onset of SAB,
hospital-acquired infection other than SAB, venous throm-
bosis, metastatic infection beyond the primary site of infec-
tion, and pressure (decubitus) ulcers. Community-onset
bacteraemia was defined as a positive blood culture col-
lected immediately prior to or within 48 hours of hospital
admission. Healthcare attendance was defined as hospital
contact not requiring overnight admission (eg. day proced-
ure unit, ambulatory care, day oncology, haemodialysis,
Hospital in the Home). Acute renal failure was recorded at
the onset of SAB according to the APACHE II score [5]
and defined as urine output < 410 mL during the initial 24
hours after onset of SAB or serum creatinine > 132 umol/L
and no prior known renal disease) [9]. Nephrotoxicity was
defined as an increase in serum creatinine by 44 μmol/L or
by more than 50% (whichever is greater) from baseline on
at least two consecutive tests during the period of antibiotic
treatment and up to 72 hours later [10]. Potential concomi-
tant nephrotoxins were defined as previously [11]. Anti-
biotic treatment was defined as empiric (prior to
susceptibility results) and definitive (predominant antibiotic
used for the longest duration during the 30 days after the
onset of SAB). Empiric therapy was deemed adequate if in
vitro susceptibility was demonstrated for the antibiotic re-
ceived. Combination therapy was defined as receipt of more
than one antibiotic with anti-staphylococcal activity against
the infecting organism for ≥ 24 hours. Formal infectious
diseases (ID) consultation was recommended at all
participating hospitals for management of patients
with SAB.
Microbiologic testing
The first positive (index) blood culture isolate from
each patient was tested in a central laboratory, in-
cluding species confirmation, Vitek®2 (bioMérieux,
Marcy l’Etoile, France) susceptibility, vancomycin and
oxacillin minimum inhibitory concentrations (MIC)
using Etest® (bioMérieux, Marcy l’Etoile, France) and
vancomycin MIC using broth microdilution (BMD)
[12] including half-step dilutions (possible concentra-
tions were 0.25, 0.375, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8,
12, 16, and 24 mg/L). Elevated vancomycin MIC was
defined as ≥ 1.5 mg/L using Etest®.
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Statistical analysis
Statistical analysis was performed using Stata v11.2 (Sta-
taCorp, College Station, TX, USA). The chi-square test
was used to compare categorical variables and the
Mann-Whitney U test was used for continuous non-
parametric variables. In order to generate binary vari-
ables from continuous data with wide ranges of plausible
values, classification and regression tree (CART) analysis
was performed to identify significant discriminatory
values associated with the outcome of interest to gener-
ate a binary variable (Salford Predictive Modeler v7.0,
Salford Systems, San Diego, CA, USA). Potentially sig-
nificant variables on univariable analysis (p<0.2) were
considered a priori for inclusion in a multivariable logis-
tic regression model. Pairwise correlation coefficients
were examined between variables that were potentially
related before inclusion in our multivariable model to
avoid collinearity, and by determining variance inflation
factors during logistic regression. Stepwise backward
elimination was performed and the Hosmer-Lemeshow
statistic was performed to test the goodness of fit of the
final model. A p-value of <0.05 was considered
statistically significant.
Results
Description of cohort
226 patients were recruited into the cohort with
complete data for 222 patients (refer Additional file 1).
The population was predominantly male, Australian-
born, and non-indigenous, with a median age of 62 years
(interquartile range [IQR] 49-76) (Additional file 2: Table
S1). Among the 51 patients (23.0%) who were admitted
to the intensive care unit (ICU), the reason was directly
related to SAB in 64% (32/50; 1 response not received).
The main reasons for ICU transfer were haemodynamic
support (10/51, 19.6%) and organ support for two or
more systems (12/51, 23.5%).
Patient exposures, comorbidities and disease severity
The most common potential exposures for acquisition
of S. aureus prior to SAB onset included companion ani-
mal exposure, recent hospitalisation, recent healthcare
attendance, and prior antibiotic therapy (Additional file
2: Table S1). Vancomycin accounted for almost one-
quarter of antimicrobials used in those with prior anti-
biotic therapy (17/75, 22.7%; 2 responses not received).
In patients where data were available, known prior col-
onisation with S. aureus was also a potential exposure
(34/75, 45.3%). The most frequent comorbidities were
cardiovascular disease, diabetes mellitus and chronic
kidney disease (Additional file 2: Table S1). Dialysis was
required in 25/48 (52.1%) patients with pre-existing end-
stage renal disease, of which 14 (56.0%) were through a
native arteriovenous fistula.
Clinical and laboratory features
The most common clinical manifestations associated
with SAB were: device-associated (81/222, 36.7%),
osteoarticular (59/222, 26.6%), skin or soft tissue infec-
tion (46/222, 20.7%), uncomplicated bacteraemia (28/
222, 12.6%), endocarditis (25/222, 11.3%), pneumonia
(15/222, 6.8%), deep abscess (13/222, 5.9%), epidural ab-
scess (10/222, 4.5%), severe sepsis including septic shock
(7/222, 3.2%), central nervous system (1/222, 0.5%), and
unknown foci (1/222, 0.5%); 22 patients (9.9%) had other
manifestations not specified including intra-abdominal,
urinary, septic thrombophlebitis, mediastinitis or oph-
thalmic foci. Echocardiography was performed in 91.9%
(204/222) patients; the majority received transthoracic
echocardiography alone (110/204, 53.9%). Endocarditis
was mainly native valve (19/25, 76.0%) and left-sided
(17/25, 68.0%). The most common device-associated in-
fections were peripheral intravenous catheters (27/81,
33.3%), haemodialysis access (10/81, 12.3%), orthopaedic
devices (10/81, 12.3%), and peripherally-inserted central
venous catheters (7/81, 8.6%). Implanted devices were
present in 69 patients (31.1%); 41/69 (59.4%) manifest
as device-associated infection with SAB. In patients
with device-associated infection, the device was re-
moved in 75.3% (61/81) within a median of one day
(IQR 0-2) of SAB onset.
Laboratory features included a median white cell
count of 11.3 x109/L (IQR 8.1-16.9), median C-reactive
protein (CRP) of 170.5 mg/L (IQR 100-277.6) [reference
range <10 mg/L] and median albumin of 30 g/L (IQR
26-34). Acute renal failure at the onset of SAB [9] was
present in 22.1% (49/222).
Microbiologic features
MRSA accounted for 25.7% (57/222) of all episodes
of SAB. The median duration of bacteraemia was
one day (IQR 1-3 days), with the longest duration of
13 days in a patient with recurrent bioprosthetic aor-
tic valve endocarditis and a chronic forearm wound
with failed split skin grafting. Elevated vancomycin
MIC ≥ 1.5 mg/L was present in 39.2% (87/222) using
Etest® and 32.9% (73/222) using BMD.
Treatment
There was significant variability in antimicrobial treat-
ment – antibiotics during a treatment course changed
for a variety of reasons such as concurrent non-S. aureus
infection requiring broader spectrum, toxicity, allergy or
intolerance; thus the predominant definitive treatment
received was flucloxacillin in 59.0% (131/222), vanco-
mycin in 26.1% (58/222), and other antibiotics in 14.9%
(33/222). Within the first seven days of therapy, the me-
dian flucloxacillin daily dose was 8 g (IQR 8-10.4 g) and
the median vancomycin daily dose was 22.2 mg/kg (IQR
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16.0-29.9 mg/kg). Nine patients with MSSA bacter-
aemia received vancomycin as the predominant anti-
biotic treatment; five of these had previous or new
allergy or intolerance to β-lactams. Empiric treatment
was adequate in 95.5% (212/222) of patients; in the
10 patients who received inappropriate empiric ther-
apy, all had MRSA bacteraemia and received beta-
lactams or aminoglycosides as initial therapy. In pa-
tients treated with definitive vancomycin, the median
vancomycin trough concentration within 96 hours of
treatment was 18 mg/L (IQR 14.2-22 mg/L).
One-third (74/222, 33.3%) of patients required sur-
gical management as part of therapy; this included
procedures to remove implanted devices such as
prostheses and portacaths as well as aspiration,
drainage or debridement.
In-hospital complications
Forty-five percent (100/222) of patients experienced at
least one pre-defined complication during hospitalisa-
tion: persistent renal impairment not returning to base-
line within 30 days after onset of SAB (35/222, 15.8%),
requirement for inpatient rehabilitation (35/222, 15.8%),
hospital-acquired infection other than SAB (30/222,
13.5%), persistent fevers ≥ 7 days (24/222, 10.8%), meta-
static infection beyond the primary site of infection (17/
222, 7.7%), venous thrombosis (7/222, 3.2%), and pres-
sure (decubitus) ulcer (3/222, 1.4%).
Adverse drug reactions (ADR) attributed to antimicro-
bial therapy occurred in 13.6% (30/221). These were at-
tributed mainly to flucloxacillin (20/30, 66.7%) and
vancomycin (7/30, 23.3%) but also included linezolid (1/
30, 3.3%) and piperacillin-tazobactam (1/30, 3.3%); in
two cases it was difficult to determine which antimicro-
bial was implicated, and one patient experienced ADR
with two antibiotics at different time points during treat-
ment. Of these ADRs, eight (8/30, 26.7%) were consid-
ered serious [13] such as sensorineural hearing loss
(vancomycin), Stevens-Johnson syndrome (vancomycin),
angioedema (flucloxacillin), and fevers requiring re-
admission to hospital (vancomycin). Nephrotoxicity oc-
curred in 19.5% (43/221) occurring in 14/58 (24.1%) pa-
tients receiving definitive vancomycin compared with
definitive flucloxacillin (24/131, 18.5%) or other antimi-
crobials (5/33, 15.2%) (p=0.526). No patients classified
with nephrotoxicity underwent renal biopsy to confirm
antibiotic-induced kidney injury. Many patients (65.6%,
145/221) also received concomitant potential nephrotox-
ins regardless of kidney injury; these included Angioten-
sin Converting Enzyme Inhibitors (ACEIs) or
Angiotensin Receptor Blockers (ARBs) (19/145, 13.1%),
loop diuretics (17/145, 11.7%), radiocontrast dye (16/
145, 11.0%), and non-steroidal anti-inflammatory drugs
(NSAIDs) (14/145, 9.7%). Concomitant aminoglycosides
(except those used in empiric treatment) were only pre-
scribed in 1.4% (2/145). Concomitant nephrotoxins were
prescribed more frequently in vancomycin-treated pa-
tients (40/57, 70.2%) in association with higher nephro-
toxicity rates compared with flucloxacillin-treated
patients (79/131, 60.3%).
Clinical outcomes
The composite 30-day endpoint of persistent bacter-
aemia, recurrent bacteraemia or all-cause mortality
was present in 14.4% (32/222). Thirty-day all-cause
mortality was 9.5% (21/222), of which the majority
were directly attributed to SAB (15/21, 71.4%). More
than two thirds were still receiving anti-
staphylococcal antibiotics (132/199, 66.3%) at 30 days.
The median length of hospital stay after onset of SAB
was 30 days (IQR 17-46 days); in some jurisdictions
this included home parenteral antibiotic therapy. All-
cause mortality at 6 months and 12 months was
19.1% (42/220) and 24.2% (53/219) respectively.
Factors associated with 30-day treatment failure
Many variables were identified as potentially significant
(p<0.2) for inclusion in the multivariable logistic regres-
sion model (Table 1). However with the low event rate,
the number of candidate variables was restricted post-
hoc to variables with p<0.1. Prior to model selection, we
removed variables that were expected to be collinear or
were directly related to outcome, eg. presence of DNR
order is directly linked with mortality and was excluded.
Age is part of APACHE II or SAPS II score however as
these scores were validated in ICU populations, we
elected to use age as the representative variable for in-
clusion. Patients with dementia are likely to reside in a
long-term care facility, so we elected to use dementia ra-
ther than residence in a long-term care facility. Using
backward stepwise elimination, variables that were asso-
ciated with 30-day treatment failure were age > 70 years,
Pitt bacteraemia score ≥ 2, CRP at onset of SAB > 250
mg/L, and persistent fevers after SAB onset. Elevated
vancomycin MIC was not associated with treatment fail-
ure in this cohort. Higher serum albumin at onset of
SAB, performing echocardiography, receipt of appropri-
ate empiric therapy, and recent healthcare attendance
prior to SAB onset were protective. Goodness of fit of
the final model appeared to be satisfactory (Hosmer-
Lemeshow statistic 4.82, p=0.777).
Discussion
Results from this cohort have generated new insights
about clinical features, treatment, and complications of
SAB, and reinforced data from previous studies. The
major findings from this study include lower than ex-
pected 30-day treatment failure and all-cause mortality,
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persistently high longer-term mortality, and morbidity
from significant in-hospital treatment complications in
patients with SAB in Australia. Whilst a number of strat-
egies have undoubtedly impacted on short-term mortal-
ity rates, future research and interventions need to be
directed at reducing other morbidity associated with
treatment and hospitalisation for SAB.
Community-onset MSSA is still the predominant
cause of SAB in Australia and tends to affect older
males [14]. Among the multiple potential risk factors
for acquisition of S. aureus analysed, the most fre-
quent was animal exposure; however no sampling or
testing of animal isolates was performed to determine
any similarities between human-animal pairs. Inter-
national travel has also been implicated in the spread
of MRSA clones [15] however this was not a com-
mon risk factor for S. aureus acquisition in our co-
hort; this may be in part due to the presence of
more MSSA in our study, and the relationship be-
tween travel and spread of MSSA clones is less well
established. In addition, higher BMI was associated
with treatment failure on univariate analysis, and
obesity has been associated with an increased risk of
colonisation with S. aureus [16], antibiotic treatment
failure and mortality [17, 18].
In-hospital complications associated with SAB can
be attributed to underlying host factors and complica-
tions related to the disease, hospitalisation, and treat-
ment administered. Here we see a significant burden
of persistent renal impairment after SAB, nosocomial
infections, persistent fevers and vascular thrombosis
during hospitalisation, and that almost one in six pa-
tients experienced an adverse event attributed to anti-
microbial therapy. Although not statistically
significant, nephrotoxicity was numerically more fre-
quent in patients receiving definitive vancomycin
compared with flucloxacillin, although concomitant
nephrotoxins were also prescribed more frequently in
vancomycin-treated patients. Whilst risk factors for
vancomycin-associated nephrotoxicity have been
Table 1 Final multivariable logistic regression model of risk factors for treatment failure at 30 days in patients with SAB
Variable Univariate analysis Multivariable logistic regression
p-value Odds ratio 95% CI p-value
Age > 70 years <0.001 4.13 1.54-11.07 0.005
Albumin (g/L) <0.001 0.88 0.80-0.96 0.003
CRP > 250 mg/L 0.002 5.41 1.93-15.19 0.001
Persistent fevers 0.029 6.65 1.73-25.62 0.006
Healthcare attendance 0.003 0.13 0.03-0.59 0.008
Pitt bacteraemia score ≥ 2a 0.04 2.94 1.03-8.39 0.044
Echocardiogram performed 0.092 0.23 0.06-0.94 0.041
Appropriate empiric treatment 0.018 0.14 0.02-0.85 0.032
DNR orderb <0.001 -
WCC (x 109/L) 0.048 -
ICU admission 0.003 -
APACHE II score > 11.5b 0.003 -
Combination treatment > 7 days 0.026 -
Severe sepsis 0.029 -
Body mass index (kg/m2) 0.037 -
Directed vancomycin treatment 0.044 -
Dementia 0.055 -
Directed flucloxacillin treatment 0.058 -
Nephrotoxicity 0.068 -
ARF at onset of SAB 0.07 -
Residence in LTCFb 0.09 -
Female sex 0.091 -
MRSA 0.098 -
aScore derived by CART analysis was > 1.5; as calculation of the score requires whole numbers, this is assumed to signify a Pitt bacteraemia score of ≥ 2
bRemoved from multivariable model due to collinearity
CRP C-reactive protein, DNR do not resuscitate order, WCC white cell count, ICU intensive care unit, ARF acute renal failure, SAB staphylococcus aureus bacteraemia,
LTCF long-term care facility, MRSA methicillin-resistant S. aureus, CART classification and regression tree, CI confidence interval
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established, such as higher steady state concentrations
[11, 19], higher daily dosage [10], longer duration of
exposure [19], and ACEI or ARBs [20], it is difficult
to determine causality due to concomitant nephrotox-
ins and changing renal function and haemodynamics
as a consequence of the infection itself [21]. Although in-
frequent, renal toxicity also occurs in anti-staphylococcal
penicillins (ASP) [22, 23] and can occur early in therapy
[24]; multiple studies have reported higher rates of adverse
events including acute kidney injury in patients receiving
ASP compared with cefazolin [25–29]. However little is
known about predictors of nephrotoxicity in flucloxacillin-
treated patients, and this should be a focus of future re-
search. Venous thrombosis is a recognised common com-
plication of short- and long-term central venous catheter-
related SAB [30], and it is possible that the effects of S. aur-
eus surface proteins and exotoxins on the coagulation
pathway may also contribute to vascular thrombosis in the
absence of venous catheters [31].
An unexpected finding was the low rate of 30-day treat-
ment failure (14.4%) in the cohort, predominantly driven
by very low all-cause mortality (9.5%). Recent but not con-
temporaneous studies in Australia and New Zealand re-
ported 30-day mortality rates of 17-20% [1, 32, 33] and
although mortality rates have been reported as low as 6.8-
13% in studies from Finland, Iceland and Taiwan, the vast
majority of patients in these cohorts had MSSA bacter-
aemia [34–36]. In a pooled analysis of over 3300 patients
from 5 large multi-centre international studies [14] 30-day
mortality was 21% - much higher than the current study.
There may be multiple reasons for this. First, identifica-
tion of an infective focus was determined in 99.5% of our
patients; the absence of an identified focus has been
strongly associated with mortality [14]. Second, more than
95% of our patients received adequate empiric therapy,
ensuring appropriate coverage in the first few critical days
of therapy, and serum vancomycin levels were therapeutic
early in therapy in those treated with vancomycin. Third,
there was attention to focus eradication and source con-
trol as this is crucial in SAB management [37]; more than
one-third of our patients required formal surgical manage-
ment, three-quarters had their device removed within a
median of 24 hours after the onset of SAB, and more than
91% underwent echocardiography. Fourth, there were
fewer isolates with elevated vancomycin MIC (compared
with our previous work [1]) which has been associated
with treatment failure and mortality [38]. This may be due
to different S. aureus genotypes in this cohort, and typing
is underway. Fifth, mortality rates in critically ill patients
with severe sepsis in Australia and New Zealand have
fallen from 2000 to 2012 [39]; this secular trend is con-
temporaneous with our current study and suggests that
supportive care and management of these patients have
improved over this time and led to the favourable clinical
outcomes found in our cohort. Although we did not spe-
cifically record formal ID consultation, all the participat-
ing hospitals had guidelines for ID consultation in patients
with SAB. Furthermore 30-day mortality rates in patients
with SAB have also fallen in our region from 20.6% in
2007-2008 [32] to 14.4% in 2013 [40]. Sixth, bias may have
been introduced as time dependent variables will have
changed the number of patients at risk for the outcome
assessment and are not captured in a logistic regression
analysis. Finally, there may have been an unintended bias
from our enrolment strategy towards less critically ill pa-
tients or towards patients where treatment success was
more likely. As informed consent was required to partici-
pate it was not appropriate to consent patients where
death was imminent; some patients with severe disease
and early death from or with SAB were therefore not
included.
All-cause mortality continues to increase in patients fol-
lowing an episode of SAB, and this has also been noted in
the literature [41–43]. Although we did not determine at-
tributable mortality at 6-months and 12-months, the in-
creased mortality seen is likely to reflect patient age and
comorbidities as well as the consequences of complications
that occur after an episode of SAB; our study demonstrates
that in-hospital complications are frequent and cause mor-
bidity that persist beyond 30 days and may contribute to
overall increased mortality in the medium term.
Elevated vancomycin MIC was detected in approxi-
mately one-third of our isolates, yet interestingly there
was no association with increased mortality or treatment
failure. We have previously observed inferior clinical
outcomes such as mortality or complicated infection in
patients whose isolates have an elevated vancomycin
MIC [1], and others have also reported similar findings
even among patients with MSSA bacteraemia [44–46].
However the association between vancomycin MIC and
poor clinical outcomes has been contentious. In the sys-
tematic review and meta-analysis performed by van Hal
et al. [38] elevated vancomycin MIC was associated with
a higher mortality rate in patients with MRSA infections,
regardless of the source of infection or MIC method-
ology. In contrast Kalil et al. [47] found no statistically
significant difference in mortality in patients with SAB.
Even when assessing vancomycin MIC by the Microscan
method, there was no difference in 90-day mortality, re-
admission or recurrence in a prospective single centre
cohort [48]. Moreover there are also problems with the
definition of elevated vancomycin MIC and differences
in MIC methodology, so currently there are limited data
to support changing clinical practice as a result of
vancomycin MIC testing in order to improve clinical
outcomes [49–51].
Predictors associated with treatment failure in this
study, notwithstanding the low event rate of 30-day
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treatment failure, comprised clinical and biochemical
variables that are easily obtained during the initial evalu-
ation of a patient with SAB such as age, Pitt bacteraemia
score, serum albumin and CRP. Significant elevations in
CRP have also been associated with mortality in bacter-
aemic patients [52] and treatment failure in MRSA bac-
teraemia [53]. Recent healthcare exposure was
associated with lower treatment failure; possible expla-
nations may include higher incidence of uncomplicated
line-associated bacteraemia, earlier hospital presentation
when unwell, or earlier appropriate MRSA therapy in
patients known to be colonised. Persistent fevers and
performing echocardiography were also predictors of
treatment response and this is presumably related to
underlying source identification and focus eradication as
important adjuncts in SAB management. Appropriate
empiric therapy was also associated with lower treat-
ment failure, consistent with the literature that delays in
appropriate therapy are associated with inferior out-
comes [54, 55], although confounding by indication has
also been observed when evaluating appropriate anti-
biotic therapy [56]. The wide confidence intervals for
the odds ratios in the multivariable analysis reflect the
low event rate of treatment failure and are another po-
tential limitation of the study.
Conclusions
In conclusion, we have documented a significant shift in
the 30-day outcomes in patients with SAB across
Australia, however in-hospital complications and longer-
term mortality remain a significant burden that should
be addressed in future studies of SAB.
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